Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Aug 15;202(4):563-6.
doi: 10.1086/654930.

Oseltamivir dosing for influenza infection in premature neonates

Edward P Acosta  1 , Penelope Jester, Peter Gal, John Wimmer, Joni Wade, Richard J Whitley, David W Kimberlin; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group
Affiliations

Oseltamivir dosing for influenza infection in premature neonates

Edward P Acosta et al. J Infect Dis. .

Abstract

Under the Emergency Use Authorization issued in April 2009, oseltamivir can be used to treat 2009 influenza A (H1N1) virus infection in children aged <1 year. No data exist on the dosing of oseltamivir in premature babies. A hospital health care worker inadvertently exposed 32 neonatal intensive care unit babies to 2009 influenza A (H1N1); a protocol was expeditiously implemented to collect samples for pharmacokinetics and dosage evaluation. Results suggest 1.0 mg/kg/dose twice daily in premature babies produces oseltamivir carboxylate exposures similar to that in older children receiving 3.0 mg/kg/dose twice daily. These results provide initial guidance on dosing oseltamivir in this vulnerable population.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Measured oseltamivir phosphate concentrations (top panel) from all cohorts in CASG 114 (blue triangles) and from premature neonates in the current study (red circles). Bottom panel: measured oseltamivir carboxylate concentrations from all cohorts in CASG 114 (blue triangles) and from premature neonates in the current study (red circles).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. FDA Issuance Letter for Tamiflu. 2009. [Accessed on September 8, 2009]. at http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM....
    1. Oo C, Hill G, Dorr A, Liu B, Boellner S, Ward P. Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1–5 years. Eur J of Clin Pharmacol. 2003;59:411–5. - PubMed
    1. Centers for Disease Control and Prevention Interim Guidance on Antiviral Recommendations for Patients with Novel Influenza A (H1N1) Virus Infection and Their Close Contacts. [Accessed on August 10, 2009]. http://www.cdc.gov/h1n1flu/recommendations.htm.
    1. FDA Issuance Letter for Tamiflu. 2009. [Accessed on May 22, 2009]. at http://www.cdc.gov/h1n1flu/eua/pdf/fda_letter_tamiflu.pdf.
    1. Kimberlin D, Acosta E, Sanchez P, Ampofo K, Vanchiere J, Englund J, Sood S, Lang D, Caserta M, Abzug M, Abughali N, Michaels M, Spigarelli M, Wan W, Jester P, Griffin J, Whitley R, NIAID Collaborative Antiviral Study Group (CASG) Oseltamivir (OST) and OST Carboxylate (CBX) Pharmacokinetics (PK) in Infants: Interim Results from a Multicenter Trial. 47th Annual Meeting of The Infectious Diseases Society of America (IDSA); Philadelphia, Pennsylvania. October 31, 2009; Abstract #1041.

Publication types